Tag Archive for: cost cuts

Novartis on Tuesday raised its full-year earnings outlook following cost cuts, a breast cancer drug trial success and progress in boosting output of a radiotherapy drug against prostate cancer.

The focus of investors and Wall Street analysts is squarely on Biogen and Eisai Co Ltd’s new drug lecanemab that slowed the progress of the disease by 27% in a trial last month.